Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

By A. Thompson, A. Muir, M. Sulkowski, D. Ge, J. Fellay, K. Shianna, T. Urban, N. Afdhal, I. Jacobson, R. Esteban and 25 more. Gastroenterology, 2010

743 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Telaprevir for retreatment of HCV infection. (2011, neutral): “Virologic failure¶ 9/49 (18) 9/48 (19) 19/27 (70)”
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014, neutral): “No response†† 18 (21) 10 (14) 4 (36) 41 (16)”
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011, methodology): “The predictive value of IL28B genotype testing for SVR is superior to that of the pretreatment HCV RNA level, fibrosis stage, age, and sex, and is higher for HCV genotype 1 virus than for genotypes 2 and 3 viruses.(31,32) There are other polymorphisms near the gene for IL28B that also predict SVR, i”